Dapagliflozin Fails to Reduce Early HF Event Risk in Hospitalized Patients
🔓 Free Teaser Cardiology / Anticoagulation Inconclusive Grade: Low
Berg DD, Patel SM, Haller PM, et al.
📅 Jan 1, 2025 · Circulation
DAPA ACT HF-TIMI 68 evaluates dapagliflozin's effect in acute heart failure, finding no short-term risk reduction.
Bayesian Synthesis Finds LAAO Fails Stroke Non-Inferiority Versus Anticoagulation
Cardiology / Anticoagulation Confirmatory Grade: Moderate
Athmakuri KS, Nandyal SR, Pamreddy HR, et al.
📅 Jul 22, 2026 · Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
LAAO reduces bleeding but not strokes compared to anticoagulation.
Extended DAPT Cuts Ischemic Events in Multivessel CAD
Cardiology / Anticoagulation Practice-changing Grade: Moderate
Tian J, Wang Z, Wang Y, et al.
📅 Jul 16, 2026 · N Engl J Med
Extended DAPT reduces ischemic events post-stent in multivessel CAD.
Aspirin Monotherapy Noninferior to Rivaroxaban Bridge After Arthroplasty
Cardiology / Anticoagulation Practice-changing Grade: High
Shivakumar S, Matino D, Zukor D, et al.
📅 Jul 12, 2026 · N Engl J Med
Aspirin matches rivaroxaban's efficacy in preventing post-surgical blood clots.
Structured Framework for Anticoagulant Bleed Management and Resumption
Cardiology / Anticoagulation Confirmatory Grade: Low
Galli M, Simeone B, Ten Berg J, et al.
📅 Jul 8, 2026 · European heart journal. Acute cardiovascular care
Bleeding risks complicate anticoagulant therapy management in cardiovascular patients.
SGLT2 Inhibitor Uptake Rises but Misses Highest-Risk HFrEF Patients
Cardiology / Anticoagulation Hypothesis-generating Grade: Low
Pulatov O, Kim SY, Grossman Z, et al.
📅 Jun 29, 2026 · BMC cardiovascular disorders
In-hospital SGLT2 initiation slashes heart failure readmissions.
Prasugrel Dose Individualization: Balancing Ischemia and Bleeding by Population
Cardiology / Anticoagulation Confirmatory Grade: Low
📅 Jun 27, 2026 · Cardiovascular therapeutics
Revisiting prasugrel: precision in antiplatelet therapy is key.
Clinical Factors Dominate Bleeding Risk in Ticagrelor Therapy
Cardiology / Anticoagulation
📅 Jun 26, 2026 · Medicina (Kaunas, Lithuania)
Age and renal function outshine genetics in ACS bleeding risk.
Andexanet Withdrawn: Reappraising Anticoagulation Reversal Strategies
Cardiology / Anticoagulation Confirmatory Grade: Low
Rocca B, Ten Cate H
📅 Jun 11, 2026 · The New England journal of medicine
Anticoagulant reversal needs evidence-driven strategies for bleeding management.
LAAC Noninferior to NOACs in Anticoagulation-Eligible AF
Cardiology / Anticoagulation Practice-changing Grade: Moderate
Doshi SK, Kar S, Nair DG, et al.
📅 Jun 4, 2026 · The New England journal of medicine
Atrial appendage closure reduces bleeding in atrial fibrillation.
ESC/EACTS Consensus Refines Antithrombotic Strategy After Bypass Surgery
Cardiology / Anticoagulation Confirmatory Grade: Low
Sandner S, Gaudino M, Agewall S, et al.
📅 May 21, 2026 · European heart journal
Balance risks: Antithrombotic therapy post-bypass under scrutiny.
Asundexian Cuts Recurrent Ischemic Stroke Without Excess Bleeding
Cardiology / Anticoagulation Practice-changing Grade: High
Sharma M, Dong Q, Hirano T, et al.
📅 Apr 16, 2026 · N Engl J Med
Could a new anticoagulant improve stroke prevention?
LAAC Noninferior to DOACs in High-Risk Atrial Fibrillation
Cardiology / Anticoagulation Hypothesis-generating Grade: Moderate
Osmancik P, Herman D, Neuzil P, et al.
📅 Jun 30, 2020 · Journal of the American College of Cardiology
LAAC proves noninferior to DOACs in high-risk AF stroke prevention.
ANNEXA-4: Andexanet Reverses Factor Xa Inhibitors Amid Thrombotic Risk
Cardiology / Anticoagulation Hypothesis-generating Grade: Low
Connolly SJ, Crowther M, Eikelboom JW, et al.
📅 Feb 7, 2019 · New England Journal of Medicine
Andexanet alfa reduces factor Xa activity by 92% in bleeding emergencies.